Premium
Localized bone regeneration around dental implants using recombinant bone morphogenetic protein‐2 and platelet‐derived growth factor‐BB in the canine
Author(s) -
Thoma Daniel S.,
Cha JaeKook,
Sapata Vitor M.,
Jung Ronald E.,
Hüsler Juerg,
Jung UiWon
Publication year - 2017
Publication title -
clinical oral implants research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.407
H-Index - 161
eISSN - 1600-0501
pISSN - 0905-7161
DOI - 10.1111/clr.12989
Subject(s) - chemistry , dentistry , bone morphogenetic protein , bone morphogenetic protein 2 , medicine , in vitro , biochemistry , gene
Objectives To test whether or not one of two biological mediators (recombinant human bone morphogenetic protein‐2 (rhBMP‐2) and recombinant human platelet‐derived growth factor (rhPDGF‐BB)) is superior to the other and compared with control groups for bone regeneration around implants based on histomorphometrical outcome measures. Materials and methods Box‐type defects (10 × 5 × 5 mm) were prepared on the buccal sides of the left and right edentulous ridge in ten mongrel dogs. Implants were placed at each site, the defects either received (i) bovine‐derived particulated bone mineral (DBBM) mixed with rhBMP‐2 and a collagen membrane (CM) (DBBM/BMP‐2), (ii) DBBM mixed with rhPDGF‐BB and CM (DBBM/PDGF), (iii) DBBM and CM (DBBM) and (iv) empty control (control). Animals were euthanized post‐surgery at 8 weeks and 16 weeks. Histomorphometrical analyses were performed. Results The mean percentages of regenerated area within total defect area amounted to 56.95% for DBBM/BMP‐2, 48.86% for DBBM/PDFG, 33.44% for DBBM and 1.59% for control at 8 weeks, and 26.79% for DBBM/BMP‐2, 23.78% for DBBM/PDFG, 30.21% for DBBM and 5.07% for control at 16 weeks with no statistically significant differences between the groups ( P > 0.05). The mean amount of regenerated bone was 26.97% for DBBM/BMP‐2, 22.02% for DBBM/PDFG, 5.03% for DBBM and 1.25% for control at 8 weeks, and at 16 weeks, these values were lower in the two groups with biological mediators (DBBM/BMP‐2 = 13.35%; DBBM/PDGF = 6.96%) and only slightly increased in group DBBM (10.68%) and the control group (4.95%) compared with 8 weeks. The first bone‐to‐implant contact values on the buccal side were minimal for DBBM/BMP‐2 (0.57 mm) and maximal for control (3.72 mm) at 8 weeks. Conclusions The use of biological mediators (rhBMP‐2 and rhPDGF‐BB) can increase the amount of bone regeneration at dehiscence‐type defects compared with controls at 8 weeks, but not at 16 weeks due to enhanced hard tissue remodeling processes.